Stock Track | Impact Therapeutics-B Soars 6.95% Intraday on Medical Insurance Inclusion and Pipeline Progress

Stock Track05-15

IMPACT THERAP-B (stock code: 07630) saw its stock price soar by 6.95% during intraday trading on Friday, extending its strong performance since its recent listing.

The surge is attributed to multiple positive developments. The company's core product, senaparib (brand name: Paishuning), has been included in China's National Medical Insurance Directory, with the pricing taking effect earlier this year, which is expected to drive sustained revenue growth. Additionally, market attention is focused on the company's pipeline candidate IMP32, a global first-in-class dual-payload ADC targeting CEACAM5, due to its differentiated positioning.

The company recently completed its IPO, which was heavily oversubscribed, and is one of only three companies globally with both a commercialized PARP1/2 inhibitor and a clinical-stage next-generation PARP1-selective inhibitor.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147308533?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 09:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147308533","market":"us","top_or_hot":-1,"title":"Stock Track | Impact Therapeutics-B Soars 6.95% Intraday on Medical Insurance Inclusion and Pipeline Progress","media":"Stock Track","content":"<p>IMPACT THERAP-B (stock code: 07630) saw its stock price soar by 6.95% during intraday trading on Friday, extending its strong performance since its recent listing.</p><p>The surge is attributed to multiple positive developments. The company's core product, senaparib (brand name: Paishuning), has been included in China's National Medical Insurance Directory, with the pricing taking effect earlier this year, which is expected to drive sustained revenue growth. Additionally, market attention is focused on the company's pipeline candidate IMP32, a global first-in-class dual-payload ADC targeting CEACAM5, due to its differentiated positioning.</p><p>The company recently completed its IPO, which was heavily oversubscribed, and is one of only three companies globally with both a commercialized PARP1/2 inhibitor and a clinical-stage next-generation PARP1-selective inhibitor.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Impact Therapeutics-B Soars 6.95% Intraday on Medical Insurance Inclusion and Pipeline Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Impact Therapeutics-B Soars 6.95% Intraday on Medical Insurance Inclusion and Pipeline Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-15 09:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>IMPACT THERAP-B (stock code: 07630) saw its stock price soar by 6.95% during intraday trading on Friday, extending its strong performance since its recent listing.</p><p>The surge is attributed to multiple positive developments. The company's core product, senaparib (brand name: Paishuning), has been included in China's National Medical Insurance Directory, with the pricing taking effect earlier this year, which is expected to drive sustained revenue growth. Additionally, market attention is focused on the company's pipeline candidate IMP32, a global first-in-class dual-payload ADC targeting CEACAM5, due to its differentiated positioning.</p><p>The company recently completed its IPO, which was heavily oversubscribed, and is one of only three companies globally with both a commercialized PARP1/2 inhibitor and a clinical-stage next-generation PARP1-selective inhibitor.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"07630","symbol_name":"英派药业-B","start_time":0,"source_url":"","article_id":"1147308533","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147308533","pubTimestamp":1778809313,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"IMPACT THERAP-B (stock code: 07630) saw its stock price soar by 6.95% during intraday trading on Friday, extending its strong performance since its recent listing.The surge is attributed to multiple...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"07630":"英派药业-B"},"translate_title":"个股追踪|Impact Therapeutics-B盘中大涨6.95%受医保纳入及管线进展影响","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"07630":1},"content_text":"IMPACT THERAP-B (stock code: 07630) saw its stock price soar by 6.95% during intraday trading on Friday, extending its strong performance since its recent listing.The surge is attributed to multiple positive developments. The company's core product, senaparib (brand name: Paishuning), has been included in China's National Medical Insurance Directory, with the pricing taking effect earlier this year, which is expected to drive sustained revenue growth. Additionally, market attention is focused on the company's pipeline candidate IMP32, a global first-in-class dual-payload ADC targeting CEACAM5, due to its differentiated positioning.The company recently completed its IPO, which was heavily oversubscribed, and is one of only three companies globally with both a commercialized PARP1/2 inhibitor and a clinical-stage next-generation PARP1-selective inhibitor.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147308533","isCrawlerRequest":true}